Trial Profile
A Safety and Tolerability Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects Birth to ≤ 48 Months of Age With Reactive Airways Disease in an Acute Setting
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 11 Aug 2023
Price :
$35
*
At a glance
- Drugs Levosalbutamol (Primary)
- Indications Bronchospasm
- Focus Adverse reactions; Registrational
- Sponsors Sunovion Pharmaceuticals
- 14 Apr 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
- 24 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 12 Jun 2014 New trial record